Back

Aortic calcium scoring from single photon emission computed tomography to predict aortic stenosis and asses prognosis in patients with transthyretin cardiac amyloidosis

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Beating the odds: advances in cardiac amyloidosis treatment Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Mr Bonnans Guillaume

Toulouse Rangueil University Hospital of Toulouse, Toulouse (France)

6 More presentations in this session

Presentation thumbnail
Cause of death in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): findings from the ATTRibute-CM study
Doctor L. Obici (Pavia, IT)
Abstract Slides Video
Presentation thumbnail
Effect of acoramidis on functional capacity and quality of life in patients with variant ATTR-CM: results from ATTRibute-CM
Professor M. Fontana (London, GB)
Abstract Slides Video
Presentation thumbnail
Effect of acoramidis on all-cause mortality, cardiovascular hospitalization and NT-proBNP in variant ATTR-CM - results from ATTRibute-CM
Professor M. Fontana (London, GB)
Abstract Slides Video
Presentation thumbnail
Acoramidis treatment is associated with a lower incidence of atrial fibrillation/atrial flutter events in patients with ATTR-CM: post-hoc analyses of the ATTRibute-CM trial
Assistant Professor K. Alexander (Palo Alto, US)
Abstract Slides Video
Presentation thumbnail
Bioactive adrenomedullin as a predictor of clinical outcomes in cardiac transthyretin amyloidosis
Mr M. Mueller (Berlin, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Beating the odds: advances in cardiac amyloidosis treatment

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Aortic calcium scoring from computed tomography for signal localization by bone scintigraphy to predict aortic stenosis and assess prognosis in patients with transthyretin cardiac amyloidosis
thumbnail
Congress Presentation
Cardiac amyloidosis Echo-Score for patients with severe aortic stenosis. The AMY-TAVI trial.
thumbnail
Congress Presentation
Long-term outcomes in patients with dual pathology aortic stenosis and cardiac amyloidosis referred for valve intervention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources